Dr. Robin Reid, M.D
NPI: 1356583355
Total Payments
$615.08
2024 Payments
$62.08
Companies
14
Transactions
33
Medicare Patients
429
Medicare Billing
$48,253
Payment Breakdown by Category
Food & Beverage$599.76 (97.5%)
Education$15.32 (2.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $599.76 | 32 | 97.5% |
| Education | $15.32 | 1 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.44 | 9 | $0 (2020) |
| Celgene Corporation | $117.53 | 6 | $0 (2022) |
| Janssen Biotech, Inc. | $78.73 | 4 | $0 (2023) |
| Amgen Inc. | $78.52 | 4 | $0 (2019) |
| GENZYME CORPORATION | $62.08 | 1 | $0 (2024) |
| Aptevo Therapeutics Inc | $27.51 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $20.64 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $19.93 | 1 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $18.97 | 1 | $0 (2018) |
| Novo Nordisk Inc | $16.78 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.08 | 1 | GENZYME CORPORATION ($62.08) |
| 2023 | $40.82 | 2 | Daiichi Sankyo Inc. ($20.64) |
| 2022 | $57.22 | 3 | Janssen Biotech, Inc. ($21.17) |
| 2020 | $44.20 | 3 | E.R. Squibb & Sons, L.L.C. ($31.45) |
| 2019 | $179.23 | 10 | E.R. Squibb & Sons, L.L.C. ($51.38) |
| 2018 | $120.71 | 7 | Celgene Corporation ($19.68) |
| 2017 | $110.82 | 7 | Celgene Corporation ($36.63) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/11/2024 | GENZYME CORPORATION | ALPROLIX (Biological), ALTUVIIIO | Food and Beverage | In-kind items and services | $62.08 | General |
| Category: Hematology | ||||||
| 12/13/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Oncology | ||||||
| 10/31/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.86 | General |
| Category: Hematology | ||||||
| 08/11/2022 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Oncology | ||||||
| 05/17/2022 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Oncology | ||||||
| 11/05/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ADVATE (Biological) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: HEMATOLOGY | ||||||
| 08/04/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $15.32 | General |
| Category: Oncology | ||||||
| 04/15/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.13 | General |
| Category: Oncology | ||||||
| 10/07/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $11.90 | General |
| Category: Oncology | ||||||
| 09/11/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.03 | General |
| Category: Oncology | ||||||
| 08/28/2019 | Amgen Inc. | MVASI (Biological), Neulasta, Vectibix | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Oncology | ||||||
| 06/21/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $11.01 | General |
| 06/13/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Oncology | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Oncology | ||||||
| 02/06/2019 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Oncology | ||||||
| 01/23/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.44 | General |
| Category: Oncology | ||||||
| 01/14/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Oncology | ||||||
| 12/13/2018 | Bayer HealthCare Pharmaceuticals Inc. | Jivi (Drug), Kovaltry | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Hematology | ||||||
| 10/31/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: Oncology | ||||||
| 08/01/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.18 | General |
| Category: Oncology | ||||||
| 03/21/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Oncology | ||||||
| 03/01/2018 | Novo Nordisk Inc | REBINYN (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Hemophilia | ||||||
| 02/28/2018 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONFOCUS, FOUNDATIONACT | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 123 | 177 | $43,384 | $14,733 |
| 2022 | 4 | 111 | 158 | $31,500 | $12,094 |
| 2021 | 4 | 100 | 149 | $28,451 | $12,322 |
| 2020 | 4 | 95 | 161 | $26,490 | $9,104 |
Total Patients
429
Total Services
645
Medicare Billing
$48,253
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 65 | $18,959 | $4,804 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 35 | $5,886 | $3,169 | 53.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 20 | $6,162 | $2,128 | 34.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 13 | $4,256 | $1,766 | 41.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 20 | $2,332 | $1,239 | 53.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $3,259 | $1,162 | 35.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 12 | $2,529 | $464.40 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 83 | $16,279 | $6,004 | 36.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 19 | $5,092 | $2,191 | 43.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $4,584 | $2,181 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 38 | 42 | $5,544 | $1,719 | 31.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 44 | $10,204 | $5,037 | 49.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 32 | 45 | $7,740 | $2,817 | 36.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 35 | 45 | $5,596 | $2,241 | 40.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $4,911 | $2,227 | 45.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 29 | 53 | $9,116 | $3,054 | 33.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 40 | 76 | $8,859 | $2,696 | 30.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 21 | $4,870 | $1,871 | 38.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $3,644 | $1,482 | 40.7% |
About Dr. Robin Reid, M.D
Dr. Robin Reid, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2009. The National Provider Identifier (NPI) number assigned to this provider is 1356583355.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robin Reid, M.D has received a total of $615.08 in payments from pharmaceutical and medical device companies, with $62.08 received in 2024. These payments were reported across 33 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($599.76).
As a Medicare-enrolled provider, Reid has provided services to 429 Medicare beneficiaries, totaling 645 services with total Medicare billing of $48,253. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Rochester, NY
- Active Since 04/06/2009
- Last Updated 01/13/2023
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1356583355
Products in Payments
- OPDIVO (Biological) $111.43
- Abraxane (Drug) $97.67
- ALPROLIX (Biological) $62.08
- Neulasta (Biological) $52.80
- DARZALEX (Biological) $41.35
- IMBRUVICA (Drug) $37.38
- IXINITY (Drug) $27.51
- MVASI (Biological) $25.72
- Enhertu (Drug) $20.64
- KEYTRUDA (Biological) $19.93
- REBLOZYL (Biological) $19.86
- Jivi (Drug) $18.97
- REBINYN (Drug) $16.78
- Xospata (Drug) $16.19
- ADVATE (Biological) $12.75
- FOUNDATIONONE (Device) $12.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Rochester
Dr. Yucai Wang, Md, Phd, MD, PHD
Student in an Organized Health Care Education/Training Program — Payments: $1.1M
Student in an Organized Health Care Education/Training Program $1.1M
Kevin Perry, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $675,526
Student in an Organized Health Care Education/Training Program $675,526
Arjun Sebastian, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $132,513
Student in an Organized Health Care Education/Training Program $132,513
Benjamin Tracy
Student in an Organized Health Care Education/Training Program — Payments: $112,594
Student in an Organized Health Care Education/Training Program $112,594
Dr. Vijay Agarwal, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $105,512
Student in an Organized Health Care Education/Training Program $105,512
Mr. Timothy Brown, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $89,868
Student in an Organized Health Care Education/Training Program $89,868